Roche’s Plan Is Working: Rituxan Bested By Follow-On GA101 In Head-To-Head Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Obinutuzumab (GA101) provided a survival advantage over the venerable Rituxan in new CLL patients, marking another milestone for Roche/Genentech in the replace-and-extend strategy for its anti-CD20 franchise.